MDCK-MRP2 - Dkfz

Forschungsschwerpunkt E
Innovative Krebsdiagnostik und -therapie
[43] Zahn A, Langhans CD, Hoffner S, Haberkorn U, Haass M,
Stremmel W, Ruehl A. Measurement of gastric emptying by 13Coctanoic
acid breath test versus scintigraphy in diabetics. Validation
of the 13C-octanoic acid breath test and relationship to gastric
symptoms and cardiovascular autonomic function. Z
Gastroenterol 2003;41:383-390.
[44] Angelescu M, Kraus T, Wiesel M, Hergesell O, Haberkorn U,
Klar E. Assessment of renal graft function by perioperative monitoring
of cortical microcirculation in kidney transplantation. Transplantation
2003; 75:1190-1196.
[45] Durani BK, Klein A, Henze M, Haberkorn U, Hartschuh W.
Somatostatin Analogue Scintigraphy in Merkel Cell Tumours. Brit J
Dermatol 2003;148:1135-1140.
[46] Haberkorn U, Altmann A. Functional genomics and radioisotope-based
imaging procedures. Ann Med 2003;35:370-9.
[47] Schönknecht P, Henze M, Hunt A, Klinga K, Haberkorn U,
*Schröder J. Hippocampal glucose metabolism is associated with
cerebrospinal fluid estrogen levels in postmenopausal women
with Alzheimer’s disease. Psychiatry Res 2003;124:125-127.
[48] Strauss LG, Dimitrakopoulou-Strauss A, Haberkorn U.
Shortened PET Data Acquisition Protocol for the Quantification of
18F-FDG Kinetics. J Nucl Med 2003:44; 1933-1939.
[49] Mattern J. Drug resistance in cancer: a multifactorial problem.
Anticancer Res 2003; 23:1769-1772.
[50] Ucur E, Mattern J, Wenger T, Okouoyo S, Schroth A,
Debatin KM, Herr I. Induction of apoptosis in experimental human
B cell lymphomas by conditional trail-expressing T cells. Br J
Cancer 2003; 89:2155-2162.
[51] Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of
prostate cancer with C-11-acetate (editorial). J Nucl Med
2003;44:556-558.
[52] Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-
Strauss A, Attigah N, Strauss LG, Mechtersheimer G, Lehnert T.
Evaluation of F-18-deoxyglucose positron emission tomography
(FDG-PET) to assess the dignity of neurogenic tumors. Eur J Surg
Onc 2003;29:536-541.
[53] *Calderon Sanchez O, *Mohammed A, *Mier W, Graham K,
Schuhmacher J, Arndt SO, Haberkorn U, Mocelo R, Eisenhut M.
2,3,5,6-Tetrafluorophenyl N-(S-Benzoylthioacetyl)glycylglycyl-paminobenzoate,
a Heterobifunctional 99mTc Ligand for
Precomplexed Antibody Labeling. Bioconjugate Chemistry
2003;14:1209-1213.
[54] Dimitrakopoulou-Strauss A, Strauss LG, Burger C,
Mikolajczyk K, Lehnert T, Bernd L, Ewerbeck V. On the fractal nature
of dynamic positron emission tomography (PET) studies. W J
Nucl Med 2003;2:306-313.
[55] Sieger S, Jiang S, Kleinschmidt J, Eskerski H, Schönsiegel F,
Altmann A, *Mier W, Haberkorn U. Tumor-specific gene expression
using regulatory elements of the glucose transporter isoform
1 gene. Cancer Gene Ther 2004;11:41-51.
[56] Wang Q, Graham K, Schauer T, Fietz T, *Mohammed A, Liu
X, Hoffend J, Haberkorn U, Eisenhut M, *Mier W. Pharmacological
properties of hydrophilic and lipophilic derivatives of
octreotate. Nucl Med Biol 2004;31:21-30.
[57] Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer PH,
Debatin KM, Herr I: Rescue of death receptor and mitochondrial
apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer
2004;108:580-587.
[58] Haberkorn U, Altmann A, *Mier W, Eisenhut M. Impact of
functional genomics and proteomics on radionuclide imaging. Sem
Nucl Med 2004:34:4-22.
[59] Doll J, Henze M, Bublitz O, Werling A, Adam LE, Haberkorn
U, *Brix G, Semmler W. Schnelle hochauflösende iterative
Bildrekonstruktion an einem Volumen-PET-System.
Nuklearmedizin, 2004;43:in press.
[60] *Efferth T, Koomägi R, Mattern J, Volm M. Lung cancer protein
expression profiles of smokers and non-smokers. Cancer Detect
Prevent, in press.
Abteilung E060
Klinische Kooperationseinheit Nuklearmedizin
[61] Barnett W, Henze M, Kröger H, Rotzoll M. New evidence
for the etiology of Kleine-Levin syndrome. Ann Neurol: submitted.
[62] Lichy MP, Henze M, Plathow C, Bachert P, Kauczor HU,
Schlemmer HP. Metabolische Bildgebung zur Verlaufskontrolle
stereotaktisch bestrahlter Gliome - Wertigkeit der 1H-MR- Spektroskopie im Vergleich zur FDG-PET und IMT-SPECT. RöFo
2004; 176:1114-1121.
[63] Haberkorn U. Positron emission tomography in the diagnosis
of mesothelioma. Lung Cancer 2004; 45: S73-S76.
[64] Clorius JH, Schlotmann A, Hoffend. J.
Belastungsrenographie bei essentieller Hypertonie. Der
Nuklearmediziner, in press.
[65] Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Ruehl A,
Irngartinger G, Stremmel W, Rudi J. Prognostic aspects of PET-
FDG kinetics in patients with metastatic colorectal carcinoma receiving
folfox chemotherapy. J Nucl Med 2004; 45: 1480-1487.
[66] Doll J, Bendl R, Henze M, Hipp PR, Brückner T, Hoess A,
Debus J, Schlegel W. Evaluation of Accuracy of Mutual Information
based CT - PET image registration: Measurements on the
precision of the registration of cerebral CT and PET volume data
by maximisation of the “mutual information”. Radiother Oncolo;
sumitted.
[67] Haberkorn U, Mier W, Eisenhut M. Scintigraphic imaging of
gene expression and gene transfer. Curr Medicinal Chem: in
press.
[68] Haberkorn U, Beuter P, Kübler W, Eskerski H, Eisenhut M,
Kinscherf R, Zitzmann S, Strauss LG, Dimitrakopoulou-Strauss A,
Altmann A. Iodide kinetics and dosimetry in vivo after transfer of
the human sodium iodide symporter gene in rat thyroid carcinoma
cells. J Nucl Med, 2004;45:827-833.
[69] Schoensiegel F, Paschen A, Sieger S, Eskerski H, *Mier W,
Rothfels H, Kleinschmidt J, Schadendorf D, Haberkorn U. MIA
(melanoma inhibitory activity) promoter mediated tissue-specific
suicide gene therapy of malignant melanoma. Cancer Gene
Therapy, 2004; 11 (6): 408-418.
[70] Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Willeke
F, Cardona S, Mechtersheimer G, Lehnert T, Strauss LG, Herfarth
C, Büchler M. Prognostic significance of preoperative (18F)
Fluorodeoxyglucose (FDG) positron emission tomography (PET)
imaging in patients with resectable soft tissue sarcomas. Ann
Surg 2003 (accepted).
[71] Dimitrakopoulou-Strauss A, Strauss LG. (eingeladene
Arbeit) Fractal dimension based on box-counting: a new parameter
for the quantification of dynamic PET studies. Harmonic and
Fractal Image Analysis 2003; (HarFA) 42-46.
[72] *Mier W, Hoffend J, Schuhmacher J, Eisenhut M,
Haberkorn U. Conjugation of DOTA using isolated phenolic active
esters: the labeling and biodistribution of albumin as blood pool
marker. Bioconjugate Chemistry: submitted.
[73] Henze M, *Mohammed A, Herfarth K, Schlemmer H,
Hoffner S, Haufe S, *Mier W, Eisenhut M, Debus J, Haberkorn U.
PET and SPECT in the detection of tumor progression in irradiated
low grade astrocytomas. An ROC analysis. J Nucl Med
2004, 45:579-586.
[74] Dietz A, Rudat V, Harms W, Jungehülsing M, Dollner R,
Henze M. Predictive value of 18F-FDG-PET in early detection of
residual disease after larynx organ preserving chemoradiation.
HNO 2004, 52:38-44.
[75] Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner
H, Saffrich R. Henze M, Eberle AN. A Gallium-labeled DOTA-α-
Melanocyte stimulating hormone analog for PET imaging of melanoma.
J Nucl Med, 2004; 45:116-123.
[76] Lichy MP, Bachert P, Henze M, Lichy CM, Debus J,
Schlemmer HP.Monitoring individual response to brain-tumour
chemotherapy: proton MR spectroscopy in a patient with recurrent
glioma after stereotactic radiotherapy. Neuroradiology
2004; 46: 126-129.
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003
331